50
Participants
Start Date
October 30, 2023
Primary Completion Date
April 30, 2024
Study Completion Date
September 30, 2027
SR-GDP
Selinexor 40mg/d,po d1,8,15; rituximab 375mg/m2, iv d1; gemcitabine 1g/m2, iv d1,8; cisplatin 25mg/m2, iv d1-3; dexamethasone 40mg,po/iv d1-4 (If patient\>70y, the dosage should be changed to 20mg). Each cycle lasts for 21 days, with a maximum of 6 cycles of combination therapy. For patients who achieved PR or better response at the end of combination therapy, they will start receiving single-agent selinexor 40mg treatment (qw) in cycles of 28 days until disease progression (PD) or unacceptable toxicity occurs.
Ruijin Hospital, Shanghai
Ruijin Hospital
OTHER